Immunovia AB (publ)
STO: IMMNOV.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Jeff Borcherding
- Employees
- 9
- Headquarters
- Lund, Sweden
- IPO year
- 2015
- Market cap
- SEK 67.4M
- Website
- https://www.immunovia.com
Loading IMMNOV…
Loading profile data…Frequently asked questions about IMMNOV
What does Immunovia AB (publ) (IMMNOV.ST) do?
Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company's product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer. Immunovia AB (publ) was incorporated in 2007 and is headquartered in...
Where does IMMNOV.ST trade?
Immunovia AB (publ) (IMMNOV.ST) trades on the Stockholm Stock Exchange.
What sector is IMMNOV.ST in?
Immunovia AB (publ) (IMMNOV.ST) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Immunovia AB (publ)?
Jeff Borcherding is the chief executive officer of Immunovia AB (publ) (IMMNOV.ST).
Where is Immunovia AB (publ) headquartered?
Immunovia AB (publ) is headquartered in Sweden.
Does IMMNOV.ST pay a dividend?
Immunovia AB (publ) (IMMNOV.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMMNOV.ST go public?
Immunovia AB (publ) (IMMNOV.ST) completed its initial public offering in 2015.